|
2024 Journal Article Identifying disease-modifying potential in myelofibrosis clinical trialsRoss, David M, Lane, Steven W and Harrison, Claire N. (2024). Identifying disease-modifying potential in myelofibrosis clinical trials. Blood Journal. doi: 10.1182/blood.2024024220 |
|
2024 Journal Article Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND StudyYeung, David T., Shanmuganathan, Naranie, Reynolds, John, Branford, Susan, Walia, Mannu, Yong, Agnes SM, Shortt, Jake, Chee, Lynette, Viiala, Nicholas, Cunningham, Ilona, Ross, David M, D'Souza, Alwyn Bernard, Wright, Matthew, Harrup, Rosemary Anne, Forsyth, Cecily Jane, Filshie, Robin, Lane, Steven W, Browett, Peter J, Grove, Carolyn S, Grigg, Andrew A and Hughes, Timothy P (2024). Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study. Blood Journal. doi: 10.1182/blood.2024024657 |
|
2024 Conference Publication 3035 – INTERFERON ALPHA THERAPY ATTENUATES LEUKAEMIC TRANSFORMATION IN JAK2V617F-DRIVEN MPN WITH TRP53-LOSSBywater, Megan, Zhang, Ranran, Grabek, Julian, Halder, Rohit, Janardhanan, Yashaswini, Cooper, Leanne, Cooper, Emily, Ross, David, Straube, Jasmin and Lane, Steven (2024). 3035 – INTERFERON ALPHA THERAPY ATTENUATES LEUKAEMIC TRANSFORMATION IN JAK2V617F-DRIVEN MPN WITH TRP53-LOSS. EXPHEM 2024, Philadelphia, PA, United States: Elsevier BV. doi: 10.1016/j.exphem.2024.104357 |
|
2024 Conference Publication 6471 Performance of eight different severity scores to predict critical care admission in paediatric inpatients treated for sepsis: a retrospective cohort studyDeef, Minnah, Bracken, Abbey, Lane, Steven, Gittings, Robert, Curran, Rachel, Foreman, Rachael, Gawne, Andrew, Carter, Bernie, Saron, Holly, Eyton-Chong, Chin-Kien, Mehta, Fulya, Siner, Sarah, Lambert, Caroline, Sefton, Gerri and Carrol, Enitan D (2024). 6471 Performance of eight different severity scores to predict critical care admission in paediatric inpatients treated for sepsis: a retrospective cohort study. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health. doi: 10.1136/archdischild-2024-rcpch.491 |
|
2024 Journal Article Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortalityScho, Jeremy, Abrams, Simon T., Jenkins, Rosalind, Lane, Steven, Wang, Guozheng and Toh, Cheng-Hock (2024). Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortality. Blood Advances, 8 (10), 2499-2508. doi: 10.1182/bloodadvances.2023012473 |
|
2024 Journal Article Survival for the fittest: guadecitabine in rel/ref AMLSheehy, Joshua and Lane, Steven W. (2024). Survival for the fittest: guadecitabine in rel/ref AML. Blood Advances, 8 (8), 2018-2019. doi: 10.1182/bloodadvances.2024012569 |
|
2024 Journal Article Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignanciesCampbell, Ashlea, Teh, Benjamin, Mulligan, Stephen, Ross, David M., Weinkove, Robert, Gilroy, Nicole, Gangatharan, Shane, Prince, Henry Miles, Szer, Jeff, Trotman, Judith, Lane, Steven, Dickinson, Michael, Quach, Hang, Enjeti, Anoop K., Ku, Matthew, Gregory, Gareth, Hapgood, Gregory, Ho, Phoebe Joy, Cochrane, Tara, Cheah, Chan, Greenwood, Matthew, Latimer, Maya, Berkahn, Leanne, Wight, Joel, Armytage, Tasman, Diamond, Peter, Tam, Constantine S. and Hamad, Nada (2024). Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies. Internal Medicine Journal, 54 (2), 328-336. doi: 10.1111/imj.16303 |
|
2024 Journal Article Autophagy prevents graft failure during murine Graft versus Host DiseaseLineburg, Katie E, Leveque-El Mouttie, Lucie, Hunter, Christopher R., Le Texier, Laeitia, McGirr, Crystal, Teal, Bianca, Blazar, Bruce R., Lane, Steven W, Hill, Geoffrey R, Levesque, Jean-Pierre and MacDonald, Kelli P.A. (2024). Autophagy prevents graft failure during murine Graft versus Host Disease. Blood Advances, 8 (8), 2032-2043. doi: 10.1182/bloodadvances.2023010972 |
|
2024 Journal Article Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemiaBruedigam, Claudia, Porter, Amy H., Song, Axia, Vroeg in de Wei, Gerjanne, Stoll, Thomas, Straube, Jasmin, Cooper, Leanne, Cheng, Guidan, Kahl, Vivian F. S., Sobinoff, Alexander P., Ling, Victoria Y., Jebaraj, Billy Michael Chelliah, Janardhanan, Yashaswini, Haldar, Rohit, Bray, Laura J., Bullinger, Lars, Heidel, Florian H., Kennedy, Glen A., Hill, Michelle M., Pickett, Hilda A., Abdel-Wahab, Omar, Hartel, Gunter and Lane, Steven W. (2024). Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. Nature Cancer, 5 (1), 47-65. doi: 10.1038/s43018-023-00653-5 |
|
2023 Journal Article Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemiaTubio-Santamaria, Nuria, Jayavelu, Ashok Kumar, Schnoeder, Tina M., Eifert, Theresa, Hsu, Chen-Jen, Perner, Florian, Zhang, Qirui, Wenge, Daniela V., Hansen, Fynn M., Kirkpatrick, Joanna M., Jyotsana, Nidhi, Lane, Steven W., von Eyss, Bjoern, Deshpande, Aniruddha J., Kuehn, Michael W. M., Schwaller, Juerg, Cammann, Clemens, Seifert, Ulrike, Ebstein, Frederic, Krueger, Elke, Hochhaus, Andreas, Heuser, Michael, Ori, Alessandro, Mann, Matthias, Armstrong, Scott A. and Heidel, Florian H. (2023). Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. Molecular Cancer, 22 (1) 196. doi: 10.1186/s12943-023-01907-7 |
|
2023 Conference Publication Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic LeukemiaKamel, Maha M., Kutyna, Monika, Ross, David M., Lane, Steven W., Thompson-Peach, Chloe, Fong, Chun Yew, Yong, Agnes S. M., Yeung, David T., Hughes, Timothy P., Hiwase, Devendra and Thomas, Daniel (2023). Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-188340 |
|
2023 Conference Publication Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic LeukemiaHiwase, Devendra, Ross, David M., Lane, Steven W., Thompson-Peach, Chloe, Fong, Chun Yew, Yong, Agnes S. M., Yeung, David T., Hughes, Timothy P. and Thomas, Daniel (2023). Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-179688 |
|
2023 Conference Publication Trp53-Loss in Hematopoietic Stem Cells Drives the Evolutionary Process of Leukemic Transformation in a Jak2 V617F-Driven Myeloproliferative Neoplasms Mouse ModelZhang, Ranran, Janardhanan, Yashaswini, Haldar, Rohit, Cooper, Leanne, Jaquelin, Sebastien, Straube, Jasmin, Bywater, Megan and Lane, Steven W. (2023). Trp53-Loss in Hematopoietic Stem Cells Drives the Evolutionary Process of Leukemic Transformation in a Jak2 V617F-Driven Myeloproliferative Neoplasms Mouse Model. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-188150 |
|
2023 Conference Publication Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic LeukemiaKutyna, Monika, Kamel, Maha M., Ross, David M., Yong, Agnes S. M., Fong, Chun Yew, Thompson-Peach, Chloe, Lane, Steven W., Yeung, David T., Hughes, Timothy P., Hiwase, Devendra and Thomas, Daniel (2023). Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-179706 |
|
2023 Conference Publication Early Generation Telomerase Deficient Mice to Investigate Clonal Hematopoiesis in AgingBruedigam, Claudia, Porter, Amy H., Straube, Jasmin, Cheng, Guidan, Heidel, Florian H. and Lane, Steven W. (2023). Early Generation Telomerase Deficient Mice to Investigate Clonal Hematopoiesis in Aging. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-191246 |
|
2023 Journal Article Clearing the way for new therapies in clonal hematopoiesisLing, Victoria Y. and Lane, Steven W. (2023). Clearing the way for new therapies in clonal hematopoiesis. Blood Advances, 7 (22), 7151-7152. doi: 10.1182/bloodadvances.2023011728 |
|
2023 Conference Publication Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML StudyYeung, David T., Shanmuganathan, Naranie, Reynolds, John, Branford, Susan, Walia, Mannu, Yong, Agnes S. M., Shortt, Jake, Burbury, Kate, Chee, Lynette C.Y., Viiala, Nick, Cunningham, Ilona, Ross, David M., D'Souza, Alwyn Bernard, Wright, Matthew P.F., Harrup, Rosemary Anne, Forsyth, Cecily, Filshie, Robin, Browett, Peter J., Lane, Steven W., Grove, Carolyn, Grigg, Andrew P., Hughes, Timothy P. and on Behalf Of The ALLG (2023). Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-172583 |
|
2023 Journal Article Genome-wide transcription factor binding maps reveal cell-specific changes in the regulatory architecture of human HSPCSubramanian, Shruthi, Thoms, Julie A I, Huang, Yizhou, Cornejo Paramo, Carina Paola, Koch, Forrest Charles, Jacquelin, Sebastien, Shen, Sylvie, Song, Emma, Joshi, Swapna, Brownlee, Christopher Peter, Woll, Petter S., Chacon-Fajardo, Diego, Beck, Dominik, Curtis, David J, Yehson, Kenneth, Antonenas, Vicki, O'Brien, Tracey, Trickett, Annette, Powell, Jason A., Lewis, Ian D, Pitson, Stuart M, Gandhi, Maher K., Lane, Steven W, Vafaee, Fatemeh, Wong, Emily, Gottgens, Berthold, Rokny, Hamid, Wong, Jason Wing Hon and Pimanda, John E (2023). Genome-wide transcription factor binding maps reveal cell-specific changes in the regulatory architecture of human HSPC. Blood Journal, 142 (17), 1448-1462. doi: 10.1182/blood.2023021120 |
|
2023 Journal Article Evaluation of a novel, multicomponent anxiety management programme for people with intellectual disability: protocol for a mixed-methods, quasi-experimental feasibility studyActon, Daniel, Williams, Jonathan, Woodrow, Ceri, Talbot, Grace, Jones, Steven, Lane, Steven and Jaydeokar, Sujeet (2023). Evaluation of a novel, multicomponent anxiety management programme for people with intellectual disability: protocol for a mixed-methods, quasi-experimental feasibility study. BMJ Open, 13 (9) e078411. doi: 10.1136/bmjopen-2023-078411 |
|
2023 Journal Article Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemiaEifert, Theresa, Hsu, Chen-Jen, Becker, Alicia L., Graessle, Sarah, Horne, Arik, Bemmann, Franziska, Zhang, Qirui, Heuser, Michael, Vasioukhin, Valeri, Scholl, Sebastian, Hochhaus, Andreas, Siegerist, Florian, Endlich, Nicole, Bullinger, Lars, Lane, Steven W., Haas, Simon, Schnoeder, Tina M. and Heidel, Florian H. (2023). Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia. Leukemia, 37 (10), 2027-2035. doi: 10.1038/s41375-023-02005-9 |
